GoldenGolden
Mount Sinai Health System

Mount Sinai Health System

Mount Sinai Health System is a hospital network in usa founded in 1997.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Dave Muoio
June 9, 2021
FierceHealthcare
Mount Sinai's commercialization arm is seeking early-stage startups that are interested in working with the health system to scale their health or biotech product over the 12-week virtual program.
Kantaro Biosciences LLC
June 2, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENS / NASDAQ: RNLX), and its...
Vivan Therapeutics
May 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- My Personal Therapeutics Ltd. (trading as Vivan Therapeutics), a UK-based company, announces an expansion of its licensed technology rights...
Emily Anthes
May 25, 2021
www.nytimes.com
The health system, which is preparing to open a new laboratory that could process 100,000 tests a day, wants to take its program to public schools this fall.
Vivan Therapeutics
May 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- My Personal Therapeutics Ltd. (trading as Vivan Therapeutics), a UK-based company, announces an expansion of its licensed technology rights...
Trellus Health
May 3, 2021
www.prnewswire.com:443
/PRNewswire/ -- Trellus Health, a leading resilience-driven connected health solution for chronic conditions, announced several important additions to its...
Pam Belluck
April 6, 2021
www.nytimes.com
The first successful direct transplant of a trachea is a medical milestone that could help thousands of people with airways damaged by ventilators and other causes.
Kantaro Biosciences LLC
March 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENX / NASDAQ: RNLX), announced today it...
Vaxalto Biotherapeutics, Inc.
March 4, 2021
www.prnewswire.com:443
/PRNewswire/ -- Vaxalto Biotherapeutics, Inc. (www.vaxalto.com), ein Biotechnologieunternehmen im präklinischen Stadium, das sich auf die Entwicklung und...
Kantaro Biosciences LLC
February 10, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing...
Kantaro Biosciences LLC
February 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kantaro Biosciences, LLC, una empresa conjunta entre Mount Sinai Health System y RenalytixAI (LSE:RENX / NASDAQ: RNLX), y el socio fabricante...
Kantaro Biosciences LLC
February 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- A Kantaro Biosciences, LLC, uma joint venture entre o Mount Sinai Health System e o RenalytixAI (LSE:RENX/NASDAQ: RNLX), e a parceira de...
Kantaro Biosciences LLC
February 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing...
Conor Hale
November 25, 2020
FierceBiotech
A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been granted an emergency green light from the FDA.
Kantaro Biosciences LLC
November 25, 2020
www.prnewswire.com:443
/PRNewswire/ -- Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ: RNLX), has received Emergency Use...
Tina Reed
May 13, 2020
FierceHealthcare
Mount Sinai Health System is launching a new Center for Post COVID Care to offer additional support for and gather crucial data from patients recovering from the virus as they transition from hospital to home.
May 8, 2020
BioSpace
Sorrento And Mount Sinai Health System To Jointly Develop COVI-SHIELDTM Antibody Therapy Targeting SARS-CoV-2 Infection (COVID-19) - read this article along with other careers information, tips and advice on BioSpace
Mark Terry
May 8, 2020
BioSpace
The partnership is aimed at creating antibody products that could act as a "protective shield" against infection by the virus that causes COVID-19, SARS-CoV-2.
Arlene Weintraub
May 8, 2020
FierceBiotech
Sorrento Therapeutics is jumping into the race to develop therapies against COVID-19, teaming up with Mount Sinai to develop a cocktail of antibodies from the blood of 15,000 recovered patients. The company's scientists believe their multipronged therapy will sidestep risks such as treatment resistance.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.